The effectiveness and cost-effectiveness of an integrated cardio-metabolic risk assessment and treatment program in primary care: the INTEGRATE study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON20643

Enrollment

28500

Registered

2013-11-26

Start date

2014-04-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiometabolic disease, prevention, screening, non-participation, primary care, effectiveness, economic evaluation. Cardiometabole ziekten, preventie, screening, non-participatie, eerstelijns gezondheidszorg, effectiviteit, economische evaluatie.

Interventions

The intervention is the CMD prevention program “Personalized Prevention Approach for CardioMetabolic Risk” (PPA CMR). We use an online risk estimation as screening tool for patients with an increased

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria for practices: - The use of an Electronic Medical Record (EMR) system, from which electronic data extraction is possible, covering approximately 90% of all Dutch general practices. Inclusion criteria for patients: - Age between 45 and 70 years, according to the guideline of the Dutch College of GPs

Exclusion criteria

Exclusion criteria: Exclusion criteria for practices: - Previously performed systematic CMD screening of the entire or a non-random sample of the practice population. Exclusion criteria for patients: - Previous diagnosis of CMD according to EMR - Receiving antihypertensive and/or lipid-lowering treatment.

Design outcomes

Primary

Measure	Time frame
1. The number of newly detected patients with a CMD in one year follow-up. 2. Change in individual risk factor (smoking, physical inactivity, obesity, unhealthy diet, blood pressure and cholesterol levels) for CMD between baseline and one year follow-up. 3. The expected number of newly detected patients with CMD and mortality after 5, 10, 20 years and lifetime. 4. Costs-effectiveness of PPA CMR 5. Non-participation and compliance in different stages of PPA CMR.	—

Measure

Time frame

1. The number of newly detected patients with a CMD in one year follow-up. 2. Change in individual risk factor (smoking, physical inactivity, obesity, unhealthy diet, blood pressure and cholesterol levels) for CMD between baseline and one year follow-up. 3. The expected number of newly detected patients with CMD and mortality after 5, 10, 20 years and lifetime. 4. Costs-effectiveness of PPA CMR 5. Non-participation and compliance in different stages of PPA CMR.

—

Secondary

Measure	Time frame
1. Difference in primary outcome 5 after implementation of different response-enhancing strategies. 2. Change in willingness to change lifestyle between baseline and one year follow-up. 3. Change in health status between baseline and one year follow up	—

Contacts

Public ContactIlse Badenbroek

Postbus 85500, 3508 GA Utrecht, Huispostnummer 6.131

integrate@umcutrecht.nl088-7568164

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)